{
    "id": 20480,
    "fullName": "RAD50 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "RAD50 loss indicates loss of RAD50 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10111,
        "geneSymbol": "RAD50",
        "terms": [
            "RAD50",
            "hRad50",
            "NBSLD",
            "RAD502"
        ]
    },
    "variant": "loss",
    "createDate": "03/30/2016",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5513,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, loss of RAD50 in BRCA1/2 wild-type ovarian cancer cell lines resulted in increased sensitivity to Lynparza (olaparib) in culture (PMID: 27016230).",
            "molecularProfile": {
                "id": 20961,
                "profileName": "BRCA1 wild-type BRCA2 wild-type RAD50 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5080,
                    "pubMedId": 27016230,
                    "title": "Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27016230"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5512,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, loss of RAD50 in BRCA1/2 wild-type ovarian cancer cell lines resulted in increased sensitivity to Rubraca (rucaparib) in culture (PMID: 27016230).",
            "molecularProfile": {
                "id": 20961,
                "profileName": "BRCA1 wild-type BRCA2 wild-type RAD50 loss"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5080,
                    "pubMedId": 27016230,
                    "title": "Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27016230"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20960,
            "profileName": "RAD50 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20961,
            "profileName": "BRCA1 wild-type BRCA2 wild-type RAD50 loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}